Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

NCT05168930 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Venetoclax
DRUG: Zanubrutinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]